The purpose of this analysis was to assess 5-year outcomes of transcatheter aortic valve implantation (TAVI) using the current technology of the self-expanding CoreValve prosthesis (Medtronic Inc., Minneapolis, Minnesota).
T ranscatheter aortic valve implantation (TAVI)
has become an accepted and less invasive treatment alternative for high-risk surgical patients with severe aortic stenosis. Short-and medium-term outcomes have been encouraging (1) (2) (3) (4) (5) .
However, data on long-term clinical outcomes, valve durability, and structural integrity remain scarce (6) (7) (8) . Although the 5-year outcomes of balloonexpandable Edwards-SAPIEN prosthesis (Edwards Lifesciences, Irvine, California) were recently reported (6) , the longest follow-up with the CoreValve (Medtronic Inc., Minneapolis, Minnesota) device thus far is 3 years, as reported by 2 different groups (7) .
The paucity of evidence on long-term durability of currently available transcatheter heart valves is one of the main issues that prevents TAVI from being used in younger and lower-risk patients. The objective of this analysis was to assess 5-year outcomes of TAVI using the current technology of the selfexpanding CoreValve prosthesis. increased late mortality compared with none or mild (63% vs. 51%; p ¼ 0.034) (Online Figure 1) . The overall neurological event rate at 5 years was 7.5%, of which more than two-thirds occurred early after the procedure ( Figure 3) ; antiplatelet/anticoagulant therapy taken by the patients at the moment of stroke/transient ischemic attack is reported in Online Appendix Table 1. During follow-up, there were 241 rehospitalizations for cardiovascular reasons in 164 (46%) patients.
Among all rehospitalizations, acute heart failure was the most frequently reason reported (42.7%), followed by requirement of permanent pacemaker implantation (17.4%) ( Table 3) . to 5.02; p ¼ 0.002) were found to be independently associated with an increased risk of repeated hospitalization due to heart failure ( Table 5) .
PROSTHESIS PERFORMANCE. The graph depicting prosthesis performances at follow-up is reported in Kaplan-Meier percentage of (A) mortality rate and (B) rate of cardiovascular mortality at 5-year follow-up. CI ¼ confidence interval. The present multicenter analysis describes the outcomes of a cohort of TAVI patients with the longest follow-up using the currently adopted selfexpanding CoreValve ReValving System device.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S
We demonstrated favorable long-term outcomes, with a 5-year survival rate of 45% and freedom from re-hospitalization for cardiac reasons of 54%.
Valve performance was excellent up to 5 years after implantation, with signs of prosthetic failure observed in only 15 patients (4.2%); notably, in only 5 cases did we report severe prosthesis dysfunction, and 2 of these were treated with a successful redo TAVI.
Contemporary evidence on survival rates after TAVI at long-term follow-up are restricted to a few studies exploring durability of previous-generation balloon-expandable devices. In our series of 353 consecutive patients, we found 5-year all-cause and cardiovascular mortality rates of 55% and 28%, respectively. To better assess the long-term durability of TAVI, we performed a landmark analysis excluding Among the main complications, we observed that bleeding and stroke occurred mainly in the earliest period after TAVI. Rehospitalization due to cardiovascular reasons after the procedure was an important issue raised by this study: it was required in 46% of patients, and among all 241 rehospitalizations, almost one-half were due to acute heart failure.
Interestingly, several noncardiac comorbidities, such as COPD, chronic renal failure, and diabetes mellitus, were associated with an increased risk of repeat hospitalization for heart failure. COPD is a wellknown comorbidity in patients hospitalized with acute heart failure and is also associated with a worse long-term prognosis (16, 17) . Similarly, diabetes mellitus and chronic renal insufficiency are commonly associated with an increased risk of adverse outcomes, including recurrent hospitalization due to heart failure (18,19). Finally, concomitant moderate or severe MR was also associated with a 2-fold increased risk of rehospitalization for decompensated acute heart failure. MR is a common finding in patients with aortic stenosis. At the time of aortic valve replacement, up to two-thirds of patients with aortic stenosis have varying degrees of MR (20) . Few studies, and with discordant results, have examined the clinical effect of pre-operative MR on outcome after TAVI (20) . However, the association between MR and the risk of rehospitalization due to heart failure has not been investigated yet. The results of this analysis tend to suggest that TAVI patients with significant pre-operative MR may potentially benefit from a staged invasive treatment of the mitral valvulopathy (i.e., transcatheter edge-to-edge technique), provided that they are anatomically suitable for that (21) . However, the real clinical-and costeffectiveness of this strategy has to be carefully evaluated in future studies.
TRANSCATHETER HEART VALVE PERFORMANCE.
As the duration of implanted transcatheter heart valves increases, valve durability and dysfunction become more crucial issues. Durability of the transcatheter valves has been a special concern and re- In the present analysis, we report satisfactory longterm valve performance in terms of transprosthetic gradient, which remained steady over time, with only a slight increase reported at the 5-year time point.
Signs of late significant prosthetic valve failure at 5 years after implantation were observed in 1.4% of population, whereas asymptomatic degeneration with only mild stenosis was reported in 2.8% of patients.
Surgical aortic bioprostheses have shown 10-year freedom from valvular failure in the range of 60% to 90%. Reported rates of structural valve deterioration requiring reoperation range widely from 6% to 47% by 12 to 20 years after surgical implantation (23) (24) (25) .
At 5 years, freedom from structural failure is generally >95%, and although early failure requiring reoperation or leading to mortality has been reported, freedom from reoperation at 5 years is also generally more than 95% (26, 27) . Finally, echocardiographic data and rates of late prosthetic failure were performed in a "survival cohort," with death possibly exerting a competing risk that may have biased our results. Caution must therefore be applied when interpreting these data.
CONCLUSIONS
Our analysis showed that TAVI with the currently Table 4 .
FIGURE 4 Prosthesis Performance
Time trends in transaortic mean gradient. TAVI ¼ transcatheter aortic valve implantation.
Barbanti et al. Long-Term Outcomes of TAVI
